EGFR and gastric cancer: Sha et al. [66] demonstrated that PTX combined with anti-EGFR-iRGD showed a higher attachment and binding affinity in three human gastric cancer cell lines and inhibited tumor growth in vivo with an approximate tumor volume reduction of 46.66% compared with the control.